Chorioretinopathy Post COVID-19: A Systematic Review and Prevalence Assessment, Unveiling Insights into an Emerging Ocular Entity
<h3>Purpose</h3><p dir="ltr">To investigate the occurrence of chorioretinopathy post-COVID-19, emphasizing demographic characteristics, medication history, clinical presentation, diagnostic evaluation, and treatment approaches, with a specific focus on the role of cortico...
Saved in:
| Main Author: | |
|---|---|
| Other Authors: | , , , , , , |
| Published: |
2024
|
| Subjects: | |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1864513544602517504 |
|---|---|
| author | Mona Mahmoud Elsakka (19487698) |
| author2 | Mostafa Hossam El Din Moawad (20600388) Eman E Labeeb (21767180) Mohamed Elneny (21767183) Abdelmonem Siddiq (14103327) Shereen Gahlan (20356283) Ibraheem M Alkhawaldeh (21767186) Hashem Abu Serhan (16003271) |
| author2_role | author author author author author author author |
| author_facet | Mona Mahmoud Elsakka (19487698) Mostafa Hossam El Din Moawad (20600388) Eman E Labeeb (21767180) Mohamed Elneny (21767183) Abdelmonem Siddiq (14103327) Shereen Gahlan (20356283) Ibraheem M Alkhawaldeh (21767186) Hashem Abu Serhan (16003271) |
| author_role | author |
| dc.creator.none.fl_str_mv | Mona Mahmoud Elsakka (19487698) Mostafa Hossam El Din Moawad (20600388) Eman E Labeeb (21767180) Mohamed Elneny (21767183) Abdelmonem Siddiq (14103327) Shereen Gahlan (20356283) Ibraheem M Alkhawaldeh (21767186) Hashem Abu Serhan (16003271) |
| dc.date.none.fl_str_mv | 2024-03-11T06:00:00Z |
| dc.identifier.none.fl_str_mv | 10.1080/08820538.2024.2323113 |
| dc.relation.none.fl_str_mv | https://figshare.com/articles/journal_contribution/Chorioretinopathy_Post_COVID-19_A_Systematic_Review_and_Prevalence_Assessment_Unveiling_Insights_into_an_Emerging_Ocular_Entity/29624675 |
| dc.rights.none.fl_str_mv | CC BY 4.0 info:eu-repo/semantics/openAccess |
| dc.subject.none.fl_str_mv | Biomedical and clinical sciences Clinical sciences Ophthalmology and optometry Chorioretinopathy corticosteroids COVID-19 ocular complications systematic review |
| dc.title.none.fl_str_mv | Chorioretinopathy Post COVID-19: A Systematic Review and Prevalence Assessment, Unveiling Insights into an Emerging Ocular Entity |
| dc.type.none.fl_str_mv | Text Journal contribution info:eu-repo/semantics/publishedVersion text contribution to journal |
| description | <h3>Purpose</h3><p dir="ltr">To investigate the occurrence of chorioretinopathy post-COVID-19, emphasizing demographic characteristics, medication history, clinical presentation, diagnostic evaluation, and treatment approaches, with a specific focus on the role of corticosteroid use.</p><h3>Methods</h3><p dir="ltr">Our protocol was registered prospectively on PROSPERO (CRD42023457712). A systematic search of databases (PubMed, Cochrane, WOS, Scopus) from November 2020 to August 2023 were performed to identify any original research reporting chorioretinopathy in COVID-19 patients. Data extraction included patient demographics, COVID-19 timeline, medication history, symptoms, diagnostic tests, and treatment outcomes. We used Joanna Briggs Institute (JBI) critical appraisal tool to assess the quality of our included studies.</p><h3>Results</h3><p dir="ltr">We identified seven case reports and two case series including 10 patients, six females and four males (mean age 36.5 years), who exhibited chorioretinopathy after COVID-19. Onset varied from 6 days to three months post-infection (average = 24.3 days). Seven patients (70%) had a history of corticosteroid use during COVID-19 treatment. Symptoms included visual loss, blurred vision, and deterioration. Diagnostic assessments revealed central serous chorioretinopathy in seven patients (70%) and punctate inner choroidopathy in two (20%). Treatment approaches varied, with corticosteroid discontinuation leading to symptom improvement, while two patients were treated with corticosteroids. Five patients who discontinued corticosteroids were reported to have improvement in visual acuity, two of them changed to 20/25 after being 20/40, two changed to 6/6, and one changed to 20/20, while the visual acuity in the sixth patient was not reported. Regarding the two patients who were treated with corticosteroids, visual acuity was reported in one case only and it improved to 20/20.</p><h3>Conclusion</h3><p dir="ltr">This systematic review states the prevalence and potential association between chorioretinopathy, and corticosteroid use in the context of COVID-19. This relation is still unclear because of the relief of symptoms in some cases after corticosteroid discontinuation, while two other cases were treated with corticosteroids and their symptoms improved.</p><h2>Other Information</h2><p dir="ltr">Published in: Seminars in Ophthalmology<br>License: <a href="http://creativecommons.org/licenses/by/4.0/" target="_blank">http://creativecommons.org/licenses/by/4.0/</a><br>See article on publisher's website: <a href="https://dx.doi.org/10.1080/08820538.2024.2323113" target="_blank">https://dx.doi.org/10.1080/08820538.2024.2323113</a></p> |
| eu_rights_str_mv | openAccess |
| id | Manara2_9c141b4eb0a7407b1a7c1254fcdca4bc |
| identifier_str_mv | 10.1080/08820538.2024.2323113 |
| network_acronym_str | Manara2 |
| network_name_str | Manara2 |
| oai_identifier_str | oai:figshare.com:article/29624675 |
| publishDate | 2024 |
| repository.mail.fl_str_mv | |
| repository.name.fl_str_mv | |
| repository_id_str | |
| rights_invalid_str_mv | CC BY 4.0 |
| spelling | Chorioretinopathy Post COVID-19: A Systematic Review and Prevalence Assessment, Unveiling Insights into an Emerging Ocular EntityMona Mahmoud Elsakka (19487698)Mostafa Hossam El Din Moawad (20600388)Eman E Labeeb (21767180)Mohamed Elneny (21767183)Abdelmonem Siddiq (14103327)Shereen Gahlan (20356283)Ibraheem M Alkhawaldeh (21767186)Hashem Abu Serhan (16003271)Biomedical and clinical sciencesClinical sciencesOphthalmology and optometryChorioretinopathycorticosteroidsCOVID-19ocular complicationssystematic review<h3>Purpose</h3><p dir="ltr">To investigate the occurrence of chorioretinopathy post-COVID-19, emphasizing demographic characteristics, medication history, clinical presentation, diagnostic evaluation, and treatment approaches, with a specific focus on the role of corticosteroid use.</p><h3>Methods</h3><p dir="ltr">Our protocol was registered prospectively on PROSPERO (CRD42023457712). A systematic search of databases (PubMed, Cochrane, WOS, Scopus) from November 2020 to August 2023 were performed to identify any original research reporting chorioretinopathy in COVID-19 patients. Data extraction included patient demographics, COVID-19 timeline, medication history, symptoms, diagnostic tests, and treatment outcomes. We used Joanna Briggs Institute (JBI) critical appraisal tool to assess the quality of our included studies.</p><h3>Results</h3><p dir="ltr">We identified seven case reports and two case series including 10 patients, six females and four males (mean age 36.5 years), who exhibited chorioretinopathy after COVID-19. Onset varied from 6 days to three months post-infection (average = 24.3 days). Seven patients (70%) had a history of corticosteroid use during COVID-19 treatment. Symptoms included visual loss, blurred vision, and deterioration. Diagnostic assessments revealed central serous chorioretinopathy in seven patients (70%) and punctate inner choroidopathy in two (20%). Treatment approaches varied, with corticosteroid discontinuation leading to symptom improvement, while two patients were treated with corticosteroids. Five patients who discontinued corticosteroids were reported to have improvement in visual acuity, two of them changed to 20/25 after being 20/40, two changed to 6/6, and one changed to 20/20, while the visual acuity in the sixth patient was not reported. Regarding the two patients who were treated with corticosteroids, visual acuity was reported in one case only and it improved to 20/20.</p><h3>Conclusion</h3><p dir="ltr">This systematic review states the prevalence and potential association between chorioretinopathy, and corticosteroid use in the context of COVID-19. This relation is still unclear because of the relief of symptoms in some cases after corticosteroid discontinuation, while two other cases were treated with corticosteroids and their symptoms improved.</p><h2>Other Information</h2><p dir="ltr">Published in: Seminars in Ophthalmology<br>License: <a href="http://creativecommons.org/licenses/by/4.0/" target="_blank">http://creativecommons.org/licenses/by/4.0/</a><br>See article on publisher's website: <a href="https://dx.doi.org/10.1080/08820538.2024.2323113" target="_blank">https://dx.doi.org/10.1080/08820538.2024.2323113</a></p>2024-03-11T06:00:00ZTextJournal contributioninfo:eu-repo/semantics/publishedVersiontextcontribution to journal10.1080/08820538.2024.2323113https://figshare.com/articles/journal_contribution/Chorioretinopathy_Post_COVID-19_A_Systematic_Review_and_Prevalence_Assessment_Unveiling_Insights_into_an_Emerging_Ocular_Entity/29624675CC BY 4.0info:eu-repo/semantics/openAccessoai:figshare.com:article/296246752024-03-11T06:00:00Z |
| spellingShingle | Chorioretinopathy Post COVID-19: A Systematic Review and Prevalence Assessment, Unveiling Insights into an Emerging Ocular Entity Mona Mahmoud Elsakka (19487698) Biomedical and clinical sciences Clinical sciences Ophthalmology and optometry Chorioretinopathy corticosteroids COVID-19 ocular complications systematic review |
| status_str | publishedVersion |
| title | Chorioretinopathy Post COVID-19: A Systematic Review and Prevalence Assessment, Unveiling Insights into an Emerging Ocular Entity |
| title_full | Chorioretinopathy Post COVID-19: A Systematic Review and Prevalence Assessment, Unveiling Insights into an Emerging Ocular Entity |
| title_fullStr | Chorioretinopathy Post COVID-19: A Systematic Review and Prevalence Assessment, Unveiling Insights into an Emerging Ocular Entity |
| title_full_unstemmed | Chorioretinopathy Post COVID-19: A Systematic Review and Prevalence Assessment, Unveiling Insights into an Emerging Ocular Entity |
| title_short | Chorioretinopathy Post COVID-19: A Systematic Review and Prevalence Assessment, Unveiling Insights into an Emerging Ocular Entity |
| title_sort | Chorioretinopathy Post COVID-19: A Systematic Review and Prevalence Assessment, Unveiling Insights into an Emerging Ocular Entity |
| topic | Biomedical and clinical sciences Clinical sciences Ophthalmology and optometry Chorioretinopathy corticosteroids COVID-19 ocular complications systematic review |